Technical Guide: Evaluating Neutralizing Antibody Titers Using NiV Pseudovirus Systems

Background: Rationale for Pseudovirus-Based Neutralization Assays

Nipah virus (NiV) is a highly pathogenic paramyxovirus classified as a Priority Pathogen by the WHO. Research with live virus requires Biosafety Level 4 (BSL-4) laboratory facilities, which significantly limits the development of vaccines and therapeutic antibodies. Pseudovirus systems address this challenge by incorporating NiV envelope glycoproteins (G and F proteins) into replication-defective viral backbones, enabling safe and efficient evaluation of neutralizing antibody titers under Biosafety Level 2 (BSL-2) conditions.

Key Advantages:

• Biosafety: Pseudoviruses are single-cycle, replication-incompetent, eliminating the need for BSL-4 containment
• Standardized Quantification: Luciferase reporter genes provide objective, reproducible quantitative readouts
• High-Throughput Screening: Compatible with 96/384-well formats for large-scale drug screening
• Antigenic Authenticity: Preserves authentic NiV entry mechanisms, including receptor binding and membrane fusion

Fig 1. Schematic Diagram of Nipah Virus Structure and Pseudovirus System Principle

System Construction: Viral Components and Design Principles

Envelope Plasmid Design: Co-expression of NiV G and F Proteins

Pseudovirus infectivity depends on the coordinated function of two NiV surface glycoproteins:

NiV G Protein (Attachment Glycoprotein)

• Function: Recognizes host cell receptors (ephrin-B2/B3) and mediates viral attachment
• Design Considerations: Use codon-optimized sequences with CMV or EF1α promoter-driven expression
• Tag Options: C-terminal HA or FLAG tags facilitate Western blot verification

NiV F Protein (Fusion Glycoprotein)

• Function: Triggers fusion between viral envelope and cell membrane, enabling viral genome release
• Critical Requirement: F protein precursor (F0) must be proteolytically cleaved into F1/F2 heterodimers to acquire fusion activity
• Cleavage Optimization Strategies:
  • Co-expression of exogenous proteases (e.g., TMPRSS2 or furin)
  • Utilization of polybasic cleavage site mutants
  • For transient expression in 293T cells, endogenous furin activity is typically sufficient for cleavage

Table 1: Construction Parameters for NiV Envelope Protein Expression Plasmids

Component	Recommended Vector	Key Elements	Verification Methods
NiV G Protein	pcDNA3.1(+)	CMV promoter, Kozak sequence, HA tag	Flow cytometry, immunofluorescence
NiV F Protein	pcDNA3.1(+)	CMV promoter, native signal peptide, no tag	Western blot (detect F1/F2 cleavage bands)
Protease Auxiliary	pCAGGS-TMPRSS2	CAG promoter, furin/TMPRSS2	Functional validation (cell-cell fusion assay)

Backbone Vector Selection: VSV-dG-Luc vs. Lentivirus

Select the appropriate replication-defective backbone based on experimental objectives:

VSV-dG-Luc System (Recommended for Neutralization Assays)

• Structure: Vesicular stomatitis virus (VSV) genome with G gene deletion, replaced by luciferase (Luc) or GFP reporter gene
• Advantages:
  • High-titer production (up to 10^8-10^9 TU/mL)
  • Rapid readout (detectable 16-24 hours post-infection)
  • Low background signal with excellent signal-to-noise ratio
• Limitations: Single infection cycle only; no integration into host genome

Lentivirus System

• Structure: HIV-1 backbone pseudotyped with NiV envelope proteins
• Advantages:
  • Integrates into host genome, suitable for stable cell line generation
  • Capable of infecting non-dividing cells
• Limitations: Lower titers (10^6-10^7 TU/mL); longer detection period (48-72 hours)

Table 2: Comparison of Pseudovirus Backbone Systems

Characteristic	VSV-dG-Luc	Lentivirus
Reporter Gene	Firefly luciferase (Luc)	GFP/Luc/Puro
Production Titer	10^8-10^9 TU/mL	10^6-10^7 TU/mL
Detection Time	16-24 hours	48-72 hours
Genome Integration	No	Yes
Applicable Cells	Broad (requires receptor expression)	Dividing/non-dividing cells
Optimal Application	High-throughput neutralization screening	Stable cell line construction

Transfection and Pseudovirus Production: Optimization Protocol

HEK293T Cell Transfection Condition Optimization

Pseudovirus yield and quality are highly dependent on transfection efficiency. The following optimization strategies are recommended:

Cell State Control

• Cell density: 70-80% confluence at transfection
• Passage number: Use low-passage cells (<P20)
• Culture medium: DMEM with 10% FBS; replace with fresh medium 4 hours before transfection

Transfection System (10 cm culture dish example)

1. Plasmid Ratio: G:F:Backbone = 1:1:2 (mass ratio)
   • Total DNA amount: 10-15 μg
   • Excess backbone plasmid ensures efficient packaging
2. Transfection Reagent: PEI 40kDa (1:3 DNA:PEI mass ratio) or Lipofectamine 3000
3. Culture Conditions: 37°C, 5% CO2; replace with complete medium 6-8 hours post-transfection

Pseudovirus Harvesting and Purification

• Harvest time: 48-72 hours post-transfection (VSV system) or 60-72 hours (lentivirus system)
• Centrifugation: 3,000 rpm for 10 minutes to remove cell debris; filter through 0.45 μm filter
• Concentration methods: Ultracentrifugation (50,000×g, 2 hours) or PEG8000 precipitation
• Storage conditions: Aliquot and store at -80°C; avoid freeze-thaw cycles

Critical Quality Control

• Titer determination: Infect target cells (e.g., Vero or 293T-ephrinB2) with serial dilutions; calculate TCID50 or relative light units (RLU)
• Specificity validation: Confirm pseudovirus neutralization using anti-NiV G/F monoclonal antibodies
• Background exclusion: Set up no-envelope control (backbone-only transfection) to assess background signal

Neutralization Assay Workflow: Standardized Protocol

Fig 2. Schematic diagram of pseudovirus neutralization assay workflow

Pre-Experimental Preparation

Target Cell Selection

• Vero Cells: African green monkey kidney cells with high ephrin-B2 expression; NiV-susceptible cell line
• 293T-ephrinB2: 293T cells stably transfected with human ephrin-B2; enhanced infection efficiency
• Cell Plating: Seed 96-well plates 24 hours before infection (1×10^4 cells/well); ensure 80-90% confluence at infection

Pseudovirus Titer Standardization

• Pre-determine pseudovirus input via pilot experiment: viral amount producing 50,000-100,000 RLU/well (within linear range)
• Avoid high MOI that may cause cytopathic effects (CPE) interfering with readouts

Neutralization Assay Procedure

Step 1: Sample Pre-treatment

• Heat-inactivate serum/antibody samples at 56°C for 30 minutes to inactivate complement
• Perform serial dilutions using serum-free DMEM (typically starting from 1:20 or 1:40, 3-fold or 4-fold serial dilutions)

Step 2: Virus-Antibody Incubation

• Mix equal volumes of pseudovirus and diluted samples (e.g., 50 μL virus + 50 μL sample)
• Incubate at 37°C, 5% CO2 for 1 hour (allows adequate antibody-virus binding)

Step 3: Infection and Detection

• Add 100 μL virus-antibody mixture to pre-plated target cells
• Incubate at 37°C for 2 hours, then replace with maintenance medium containing 2% FBS
• Continue culture for 16-24 hours (VSV system) or 48 hours (lentivirus system)

Step 4: Luciferase Readout

• Remove medium; gently wash cells with PBS
• Add cell lysis buffer
• Use luciferase detection reagent (e.g., Bright-Glo or Steady-Glo)
• Detect RLU values using chemiluminescence plate reader; integration time 0.5-1 second/well

Data Analysis and IC50 Calculation

Neutralization Percentage Calculation:

Neutralization (%) = [1 - (Sample RLU - Background RLU) / (Virus Control RLU - Background RLU)] × 100

IC50/ID50 Calculation:

• Perform non-linear regression analysis using GraphPad Prism or similar software (four-parameter logistic fit)
• Report 50% inhibitory concentration (IC50) or 50% inhibitory dilution (ID50)
• Set quality control criteria: Positive control antibody IC50 should fall within ±2 standard deviations of historical mean values

Table 3: Neutralization Assay Control Setup

Control Type	Setup Method	Expected Result	Quality Control Significance
Virus Control	Pseudovirus + medium (no antibody)	High RLU signal (set as 0% inhibition)	Confirm pseudovirus infectivity
Cell Control	Target cells only (no virus)	Background RLU signal	Exclude cell autofluorescence
Positive Control	Known neutralizing antibody (e.g., m102.4 analog)	Dose-dependent inhibition	Validate assay system functionality
Negative Control	Irrelevant antibody or negative serum	No or low inhibition (<20%)	Exclude non-specific effects
Pseudovirus Control	Envelope-free backbone virus	Background RLU level	Exclude residual backbone virus infection

Product Recommendations: Critical Reagents and Controls

To ensure experimental reproducibility and standardization, the following validated reagents are recommended:

Table 4: Recommended Critical Reagents and Controls

Product Category	Recommended Product	Catalog/Source	Application
Recombinant Proteins	NiV G protein ectodomain (aa1-602, Fc-tagged)	Custom or commercial sources	Immunogen for antibody production, ELISA control
	NiV F protein ectodomain (aa1-488, prefusion-stabilized mutant)	Custom or commercial sources	Conformation-specific antibody screening, vaccine design
Positive Antibodies	Anti-NiV G neutralizing mAb (e.g., m102.4 analog)	Literature-reported or custom production	Positive control, validate pseudovirus system
	Anti-NiV F neutralizing mAb (targeting F1 subunit)	Literature-reported or custom production	Assess F protein-dependent neutralization
Detection Systems	Bright-Glo Luciferase Assay System	Promega E2610	High-sensitivity chemiluminescence detection
	Firefly Luciferase Reporter Gene Assay Kit	Various brands	Standardized RLU readout
Cell Lines	Vero CCL-81	ATCC	Standard target cells
	293T-ephrinB2 stable line	Laboratory-constructed or custom	Enhanced infection efficiency

Critical Notes:

• Recombinant F protein should be confirmed in prefusion-stabilized conformation, which exposes major neutralizing epitopes
• Positive control antibodies should be aliquoted and stored at -80°C; avoid repeated freeze-thaw cycles that may reduce titers
• Regularly calibrate inter-batch experimental variation using reference sera with known titers

Troubleshooting Guide

Table 5: Common Issues and Solutions

Issue	Possible Cause	Solution
Low pseudovirus titer	Insufficient F protein cleavage efficiency	Co-express furin or TMPRSS2; verify F protein sequence integrity
	Low transfection efficiency	Optimize DNA:PEI ratio; ensure healthy cell status
High background signal	Residual G protein in backbone	Use higher purity plasmid preparation; optimize ultracentrifugation purification
	Target cell autofluorescence	Switch to lower passage cells; adjust lysis conditions
Atypical neutralization curve	Excessive pseudovirus input	Dilute virus to linear range; reduce MOI
	Antibody-dependent enhancement (ADE)	Test low-dilution sera; use Fc-mutant antibody controls
Poor experimental reproducibility	Pseudovirus batch variation	Prepare large virus batches at once; titrate validate each batch
	Cell status fluctuation	Strictly standardize cell culture; use same batch of FBS

Applications and Future Perspectives

The NiV pseudovirus system extends beyond neutralizing antibody detection to various applications:

• Entry Inhibitor Screening: High-throughput screening of small molecule compound libraries targeting receptor binding (ephrin-B2/B3) or membrane fusion
• Vaccine Immunogenicity Assessment: Comparative analysis of neutralizing antibodies induced by different vaccine platforms (mRNA, recombinant protein, viral vectors)
• Escape Mutation Monitoring: Directed evolution screening of escape mutant strains to assess antibody resistance risks
• Cross-Protection Studies: Utilize Hendra virus (HeV) pseudovirus systems to evaluate cross-neutralization activity

Safety and Regulatory Considerations

Although pseudoviruses are handled in BSL-2 laboratories, the following precautions remain essential:

• Treat all pseudovirus-containing materials as potentially infectious substances
• Conduct virus manipulation in biosafety cabinets (BSC-II)
• Treat liquid waste with 1% sodium hypochlorite for 30 minutes before disposal
• Ensure laboratory personnel receive NiV-specific biosafety training

References

1. Tamin, A., et al. (2009). Functional properties of the fusion and attachment glycoproteins of Nipah virus. Virology, 386(1), 157-171.
2. Bossart, K. N., et al. (2012). Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. Journal of Virological Methods, 179(2), 245-253.
3. Kalodimou, G., et al. (2022). Development and validation of a pseudovirus-based assay for Nipah virus neutralizing antibodies. Journal of Virological Methods, 299, 114345.
4. Mire, C. E., et al. (2019). A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. Science Translational Medicine, 11(494), eaau5658.
5. Wang, Z., et al. (2021). Structure and function of the Nipah virus fusion glycoprotein. Current Opinion in Virology, 48, 1-9.
6. Geisbert, T. W., et al. (2014). Medical countermeasures against the henipaviruses: Current status and future directions. Antiviral Research, 108, 1-13.
7. DeBuysscher, B. L., et al. (2013). A rapid immunodiagnostic test for the detection of IgM antibodies against Nipah virus. Journal of Virological Methods, 193(1), 33-39.
8. Peeples, M. E. (2021). Paramyxovirus entry: Lessons from the Nipah virus F and G glycoproteins. Viruses, 13(8), 1556.